Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

9.300 +8.849 (+1959.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 296,247
Open 9.090
Bid (Size) 9.000 (3)
Ask (Size) 9.900 (10)
Prev. Close 0.4515
Today's Range 8.741 - 10.10
52wk Range 0.3540 - 10.10
Shares Outstanding 407,265,944
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Via Benzinga
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
Action Taken to Maintain Company’s Nasdaq Listing 
From Amarin Corporation plc
Via GlobeNewswire

Performance

YTD
+1676.2%
+1676.2%
1 Month
+2168.3%
+2168.3%
3 Month
+1706.9%
+1706.9%
6 Month
+1497.9%
+1497.9%
1 Year
+871.8%
+871.8%

More News

Read More
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
From Amarin Corporation plc
Via GlobeNewswire
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of
From Amarin Corporation plc
Via GlobeNewswire
Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action
From Amarin Corporation plc
Via GlobeNewswire
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
From Amarin Corporation plc
Via GlobeNewswire
Earnings Scheduled For March 12, 2025
Via Benzinga
Amarin Receives National Reimbursement for VAZKEPA® in Austria
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
From Amarin Corporation plc
Via GlobeNewswire
Amarin Receives National Reimbursement for VAZKEPA® in Italy
From Amarin Corporation plc
Via GlobeNewswire
Amarin Appoints Peter Fishman Chief Financial Officer
From Amarin Corporation plc
Via GlobeNewswire
Top 3 Health Care Stocks You'll Regret Missing In Q4
Via Benzinga
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual
From Amarin Corporation plc
Via GlobeNewswire
Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces Two Upcoming Investor Events
From Amarin Corporation plc
Via GlobeNewswire
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual
From Amarin Corporation plc
Via GlobeNewswire
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
From Amarin Corporation plc
Via GlobeNewswire
Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
3 Breakthrough Stocks Under $10 Set for Massive Upside
Via InvestorPlace
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
From Amarin Corporation plc
Via GlobeNewswire

Frequently Asked Questions

Is Amarin Corporation plc - American Depositary Shares publicly traded?
Yes, Amarin Corporation plc - American Depositary Shares is publicly traded.
What exchange does Amarin Corporation plc - American Depositary Shares trade on?
Amarin Corporation plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Amarin Corporation plc - American Depositary Shares?
The ticker symbol for Amarin Corporation plc - American Depositary Shares is AMRN on the Nasdaq Stock Market
What is the current price of Amarin Corporation plc - American Depositary Shares?
The current price of Amarin Corporation plc - American Depositary Shares is 9.300
When was Amarin Corporation plc - American Depositary Shares last traded?
The last trade of Amarin Corporation plc - American Depositary Shares was at 04/11/25 04:00 PM ET
What is the market capitalization of Amarin Corporation plc - American Depositary Shares?
The market capitalization of Amarin Corporation plc - American Depositary Shares is 3.79B
How many shares of Amarin Corporation plc - American Depositary Shares are outstanding?
Amarin Corporation plc - American Depositary Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.